Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Swedish Orphan Biovitrum AB ( (SE:SOBI) ).
Sobi reported a strong start to 2026, with first-quarter revenue up 24% at constant exchange rates to SEK 7.18 billion and an adjusted EBITA margin of 38%, driven by robust growth in its strategic portfolio and flagship haematology and immunology drugs. Altuvoct and Doptelet fuelled a 24% revenue increase in haematology, while Gamifant and Kineret underpinned similar growth in immunology, lifting earnings per share by about 50% year on year.
The company advanced its pipeline and long-term growth agenda by launching Aspaveli for C3G and IC-MPGN in Europe, filing Tryngolza with the EMA for severe hypertriglyceridaemia, and completing the acquisition of Arthrosi Therapeutics to add a late-stage gout candidate. These moves expand Sobi’s specialty care and rare-disease portfolio, support its 2030 revenue ambition of SEK 55 billion and are expected to enhance its growth and margin profile over the coming years.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK500.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company focused on treatments for rare diseases, with core franchises in haematology and immunology. Its portfolio includes therapies such as Altuvoct, Doptelet, Gamifant, Kineret and Aspaveli, targeting conditions like haemophilia, severe inflammatory disorders and complement-mediated kidney disease.
Average Trading Volume: 426,147
Technical Sentiment Signal: Buy
Current Market Cap: SEK138B
For a thorough assessment of SOBI stock, go to TipRanks’ Stock Analysis page.